(Finance) – After Friday’s jump, continues to rise to Piazza Affari the title Record yourselfa multinational pharmaceutical company that is part of the FTSE MIB, following the agreement with Sanofi for theacquisition of global rights to Enjaymo (sutimlimab), a biologic drug for rare diseases.
Equitywhich confirms the “Buy” recommendation and increases the target price at 60.5 euros per share (+5%), highlights that Friday’s conference call revealed an EBITDA margin higher than the average for rare diseases and strong patent protection. “We estimate that financial flexibility allows for new deals with a potential firepower of even more than 1 billion euros, although we believe that in the short term the focus will probably be on the integration of the latest acquisition”, we read in the research.
Among other analysts, Deutsche Bank increased the target price to 52 euros per share from the previous 48 euros, while RBC increased it to 53 euros per share from the previous 50.5 euros.
Improve the performance of Record yourselfThat it stands at 52.6 euroswith a 1.45% increase. Operationally, expectations are for a continuation of the day in a positive direction with resistance seen at 52.88 and subsequently at 53.63. Support at 52.13.